Abstract:
A method for improving CdZnTe-based gamma-ray detectors is presented. A CdZnTe detector/crystal is exposed to acoustic waves. After exposure to acoustic waves, the CdZnTe gamma-detector gains higher resistivity and exhibits better spectral resolution and greater sensitivity. Further, when a batch of detectors is made according to the method of the present invention, the properties of the crystals are more homogenous, allowing for cheaper and more standardized detectors.
Abstract:
Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue.
Abstract:
A method of efficiently extracting the pull-in parameters of an electrostatically activated actuator. The actuator is modeled as an elastic element. For each of a plurality of deformations of the elastic element, a corresponding voltage is calculated. The highest such voltage is the pull-in voltage of the actuator. The corresponding deformation is the pull-in deformation of the actuator. Each deformation is defined by fixing a displacement of one degree of freedom of the elastic body and calculating corresponding equilibrium displacements of all the other degrees of freedom without the application of any external mechanical forces to ensure equilibrium. The actuator is altered to optimize whichever pull-in parameter is relevant to the desired application of the actuator.
Abstract:
The present invention provides methods of diagnosing cancer in a test subject, comprising exposing an array of chemically sensitive sensors comprising a material selected from the group consisting of conductive nanostructures coated with an organic coating, a conducting polymer and a conductive polymer composite, to a blood sample and a urine sample obtained from the test subject, and analyzing output signals of the chemically sensitive sensors upon exposure of the array to the blood sample and the urine sample. The array of the chemically sensitive sensors can be a part of a portable medical device. Further provided is a method of diagnosing cancer in a test subject, comprising measuring and analyzing levels of a set of volatile organic compounds (VOCs) in a blood sample and a urine sample obtained from the test subject.
Abstract:
The invention disclosed herein concerns an amperometric enzyme-based biosensor which exhibits high accuracy, high bioelectrocatalytic currents, linear response, low overpotentials and stability.
Abstract:
Provided is a system for continuous generation of gases, the system including an electrochemical device and an active- material regeneration device.
Abstract:
An electro-optic system, the electro-optic system that may include an input port that is configured to receive a bandpass signal that conveys information; wherein the bandpass signal is a radio frequency (RF) signal; an optical carrier source that is configured to generate an optical carrier signal having an optical carrier frequency; at least one electrical bias circuit that is configured to generate at least one electrical bias signal; an electro-optic modulation circuit that is linear at the optical field; a manipulator that is configured to (a) receive the at least one electrical bias signal and the bandpass signal, (b) generate, based on the at least one electrical bias signal and the bandpass signal, at least one modulating signal; wherein the electro-optic modulation circuit is configured to modulate the optical carrier by the at least one modulating signal to provide an output optical signal that comprises at least one optical pilot tone and at least one optical sideband that conveys the information.
Abstract:
A molecular data storage system is presented for encoding data-block(s). The system includes one or more populations of molecular sequences, each population encoding a respective one of the data-blocks. Each molecular sequence comprises a data encoding section comprising a sequence of similar predetermined length N of short k-mers, whereby in each population the data encoding sections of all molecular sequences have the similar predetermined length N. The short k-mers serve as data encoding building blocks of the data encoding sections, whereby valid short k-mers serving as data encoding building blocks form a subset of a building-block-set consisting of a number Z of different preselected short k-mers each presenting a unique combination of a number k of bases of a preselected set of bases, characterized in that all the Z types of short k-mers in said building-block-set have a similar predetermined size k≥2 (plurality) of bases. The data encoding sections collectively encode a sequence of encoded alphabet letters S=(π1, π2, . . . , πn . . . , πN−1, πN). Each valid encoded alphabet letter πn at location n of the sequence S of alphabet letters is characterized by occurrence of a predetermined plurality of different types of short k-mers of the building-block-set in a corresponding location n along the data encoding sections of the plurality of molecular sequences of said population.
Abstract:
The invention provides isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within said peptides. Pharmaceutical compositions comprising said peptides and antibodies are also disclosed as well as methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
Abstract:
A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.